Company profile for Fore Biotherapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

To address the unmet needs of a diverse patient population, we’ve developed unique AI-supported drug discovery methods that accurately identify oncogenic yet untargeted mutations, then match them to potential drug candidates in a tumor-agnostic fashion.We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. Deeply rooted in science and innovation, our ...
To address the unmet needs of a diverse patient population, we’ve developed unique AI-supported drug discovery methods that accurately identify oncogenic yet untargeted mutations, then match them to potential drug candidates in a tumor-agnostic fashion.We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. Deeply rooted in science and innovation, our vision is to compassionately contribute to solving cancer.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
3675 Market Street Philadelphia, PA 19104
Telephone
Telephone
267-641-7575
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251104670692/en/FORE-Biotherapeutics-to-Participate-in-Upcoming-Investor-Conferences

BUSINESSWIRE
04 Nov 2025

https://www.businesswire.com/news/home/20251013525585/en/FORE-Biotherapeutics-to-Host-Virtual-Key-Opinion-Leader-Roundtable-Discussion-on-Plixorafenibs-Potential-to-Disrupt-the-BRAF-Market-to-Benefit-Patients

BUSINESSWIRE
13 Oct 2025

https://www.businesswire.com/news/home/20250924931169/en/FORE-Biotherapeutics-Announces-Positive-Outcome-From-a-Planned-Interim-Efficacy-Analysis-for-the-FORTE-Basket-Study-Evaluating-Plixorafenib-as-a-Monotherapy-for-Recurrent-or-Progressive-BRAF-V600-Primary-CNS-Tumors

BUSINESSWIRE
24 Sep 2025

https://www.businesswire.com/news/home/20250912908699/en/FORE-Biotherapeutics-Presents-Phase-12a-Plixorafenib-Data-Demonstrating-Prolonged-Duration-of-Effect-in-BRAF-Altered-Thyroid-Cancers-at-American-Thyroid-Association-2025-Annual-Meeting

BUSINESSWIRE
12 Sep 2025

https://www.businesswire.com/news/home/20250827877608/en/FORE-Biotherapeutics-to-Participate-in-Upcoming-Investor-Conferences

BUSINESSWIRE
27 Aug 2025

https://www.businesswire.com/news/home/20250527398002/en/FORE-Biotherapeutics-to-Participate-in-the-Jefferies-Global-Healthcare-Conference

BUSINESSWIRE
27 May 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty